Abstract
Neisseria meningitidis (N. meningitidis) causes sepsis, epidemic meningitis, and sometimes also meningoencephalitis. Despite early antibiotic treatment, mortality and morbidity remain significant. We present recent studies on meningococcal disease with focus on the pathophysiology caused by bacterial virulence factors and the host immune responses. The bacterial outer membrane lipopolysaccharide and non-lipopolysaccharide components are related to meningococcal adhesion and invasion, while the host immune reactions propagate inflammation and neurodegeneration. Hence, bacterium-host interactions are key determinants of the clinical course and risk of fatal outcome. Accordingly, successful treatment of severe meningococcal disease requires not only antibiotics but also adjuvants targeting the released endotoxins and the host immune/inflammatory responses. This review highlights the most recent data and current knowledge on molecular mechanisms of meningococcal disease and explains how host immune responses ultimately may aggravate neuropathology and the clinical prognosis. Within this context, particular importance is paid to the endotoxic components that provide potential drug targets for novel neuroprotective adjuvants, which are needed in order to improve the clinical management of meningoencephalitis and patient prognosis.
Keywords: Inflammation, meningitis, infection, neuroprotection, medical treatment, N. meningitidis, nasopharynx, meningococcemia, meningococcal disease, L-glycero-D-mannoheptopyranoside, transferrin, lactoferrin, LPS, OMPs, CD66, ROS, brain parenchyma, Intraparenchymal neuropathology, encephalitis, hypertrophy, hyperplasia
CNS & Neurological Disorders - Drug Targets
Title: Meningococcal Disease and Future Drug Targets
Volume: 10 Issue: 1
Author(s): L. K. Gammelgaard, H. Colding, S. H. Hartzen and M. Penkowa
Affiliation:
Keywords: Inflammation, meningitis, infection, neuroprotection, medical treatment, N. meningitidis, nasopharynx, meningococcemia, meningococcal disease, L-glycero-D-mannoheptopyranoside, transferrin, lactoferrin, LPS, OMPs, CD66, ROS, brain parenchyma, Intraparenchymal neuropathology, encephalitis, hypertrophy, hyperplasia
Abstract: Neisseria meningitidis (N. meningitidis) causes sepsis, epidemic meningitis, and sometimes also meningoencephalitis. Despite early antibiotic treatment, mortality and morbidity remain significant. We present recent studies on meningococcal disease with focus on the pathophysiology caused by bacterial virulence factors and the host immune responses. The bacterial outer membrane lipopolysaccharide and non-lipopolysaccharide components are related to meningococcal adhesion and invasion, while the host immune reactions propagate inflammation and neurodegeneration. Hence, bacterium-host interactions are key determinants of the clinical course and risk of fatal outcome. Accordingly, successful treatment of severe meningococcal disease requires not only antibiotics but also adjuvants targeting the released endotoxins and the host immune/inflammatory responses. This review highlights the most recent data and current knowledge on molecular mechanisms of meningococcal disease and explains how host immune responses ultimately may aggravate neuropathology and the clinical prognosis. Within this context, particular importance is paid to the endotoxic components that provide potential drug targets for novel neuroprotective adjuvants, which are needed in order to improve the clinical management of meningoencephalitis and patient prognosis.
Export Options
About this article
Cite this article as:
K. Gammelgaard L., Colding H., H. Hartzen S. and Penkowa M., Meningococcal Disease and Future Drug Targets, CNS & Neurological Disorders - Drug Targets 2011; 10 (1) . https://dx.doi.org/10.2174/187152711794488584
DOI https://dx.doi.org/10.2174/187152711794488584 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Separating Fact from Fiction: The Data Behind Allergies and Side Effects Caused by Penicillins, Cephalosporins, and Carbapenem Antibiotics
Current Pharmaceutical Design State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Biomedical Exploitation of Self Assembled Peptide Based Nanostructures
Current Protein & Peptide Science Advances in Drug Discovery and Development for Pediatric Tuberculosis
Mini-Reviews in Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine
CNS & Neurological Disorders - Drug Targets Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry